Table 3.
Platelet aggregability and PRI of VASP-P in prasugrel- and clopidogrel-treated patients with acute STEMI (analysis of combined T2D and ND patients and analysis of T2D patients, marked as T2D patients).
| LTA with ADP induction (%) | Prasugrel-treated patients | Clopidogrel-treated patients | Significance |
|---|---|---|---|
| Sample 1 | 45.9 ± 26.2% | 59.2 ± 18.8% | p < 0.05 |
| Sample 2 | 24.9 ± 17.7% | 51.7 ± 22.8% | p < 0.001 |
|
| |||
| LTA with ADP induction (%) T2D patients |
Prasugrel-treated T2D patients | Clopidogrel-treated T2D patients | Significance |
|
| |||
| Sample 1 | 43.3 ± 20.6 | 63.5 ± 22.8 | p < 0.05 |
| Sample 2 | 22.9 ± 16.9 | 60.3 ± 26.6 | p < 0.01 |
|
| |||
| PRI of VASP-P analysis (%) | Prasugrel-treated patients | Clopidogrel-treated patients | Significance |
|
| |||
| Sample 1 | 52.7 ± 29.7% | 68.9 ± 19.9 | p < 0.05 |
| Sample 2 | 26.3 ± 24.3% | 51.8 ± 22.8% | p < 0.01 |
|
| |||
| PRI of VASP-P analysis (%) T2D patients |
Prasugrel-treated T2D patients | Clopidogrel-treated T2D patients | Significance |
|
| |||
| Sample 1 | 46.8 ± 33.5 | 78.3 ± 13.0 | p < 0.05 |
| Sample 2 | 18.7 ± 15.7 | 56.8 ± 18.7 | p < 0.01 |